MX2018009498A - Anticuerpos anti-tnf, composiciones, métodos y uso para el tratamiento o la prevención de la diabetes tipo 1. - Google Patents
Anticuerpos anti-tnf, composiciones, métodos y uso para el tratamiento o la prevención de la diabetes tipo 1.Info
- Publication number
- MX2018009498A MX2018009498A MX2018009498A MX2018009498A MX2018009498A MX 2018009498 A MX2018009498 A MX 2018009498A MX 2018009498 A MX2018009498 A MX 2018009498A MX 2018009498 A MX2018009498 A MX 2018009498A MX 2018009498 A MX2018009498 A MX 2018009498A
- Authority
- MX
- Mexico
- Prior art keywords
- diabetes
- prevention
- compositions
- treatment
- type
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/002—Packages specially adapted therefor, e.g. for syringes or needles, kits for diabetics
- A61M5/003—Kits for diabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31533—Dosing mechanisms, i.e. setting a dose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31565—Administration mechanisms, i.e. constructional features, modes of administering a dose
- A61M5/31566—Means improving security or handling thereof
- A61M5/31573—Accuracy improving means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31565—Administration mechanisms, i.e. constructional features, modes of administering a dose
- A61M5/3159—Dose expelling manners
- A61M5/31591—Single dose, i.e. individually set dose administered only once from the same medicament reservoir, e.g. including single stroke limiting means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662291673P | 2016-02-05 | 2016-02-05 | |
| PCT/US2017/016175 WO2017136524A2 (en) | 2016-02-05 | 2017-02-02 | Anti-tnf antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018009498A true MX2018009498A (es) | 2019-05-06 |
Family
ID=59500155
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018009498A MX2018009498A (es) | 2016-02-05 | 2017-02-02 | Anticuerpos anti-tnf, composiciones, métodos y uso para el tratamiento o la prevención de la diabetes tipo 1. |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US10465003B2 (https=) |
| EP (1) | EP3411504A4 (https=) |
| JP (1) | JP2019509988A (https=) |
| KR (1) | KR20180105711A (https=) |
| CN (1) | CN109072303A (https=) |
| AU (1) | AU2017215317A1 (https=) |
| BR (1) | BR112018015754A2 (https=) |
| CA (1) | CA3012465A1 (https=) |
| MA (1) | MA43982A (https=) |
| MX (1) | MX2018009498A (https=) |
| WO (1) | WO2017136524A2 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018119142A1 (en) | 2016-12-21 | 2018-06-28 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| LT3781941T (lt) | 2018-04-20 | 2026-04-10 | Janssen Biotech, Inc. | Chromatografijos kolonėlės kvalifikavimas gamybos būduose, skirtuose anti-tnf antikūnų kompozicijoms gaminti |
| MA54750A (fr) * | 2019-01-15 | 2021-11-24 | Janssen Biotech Inc | Compositions d'anticorps anti-tnf et procédés pour le traitement de l'arthrite idiopathique juvénile |
| BR112021014267A2 (pt) * | 2019-01-23 | 2022-02-15 | Janssen Biotech Inc | Composições de anticorpo anti-tnf e métodos para o tratamento de artrite psoriática |
| KR20210141976A (ko) | 2019-03-14 | 2021-11-23 | 얀센 바이오테크 인코포레이티드 | 항-tnf 항체 조성물의 제조 방법 |
| JP7662529B2 (ja) | 2019-03-14 | 2025-04-15 | ヤンセン バイオテツク，インコーポレーテツド | 抗ｔｎｆ抗体組成物を産生するための方法 |
| CA3133381A1 (en) * | 2019-03-14 | 2020-09-17 | Janssen Biotech, Inc. | Manufacturing methods for producing anti-tnf antibody compositions |
| IL322315A (en) | 2019-05-14 | 2025-09-01 | Provention Bio Inc | Methods and preparations for preventing type 1 diabetes |
| WO2020234834A1 (en) | 2019-05-23 | 2020-11-26 | Janssen Biotech, Inc. | Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha |
| WO2021028752A1 (en) * | 2019-08-15 | 2021-02-18 | Janssen Biotech, Inc. | Anti-tfn antibodies for treating type i diabetes |
| WO2021075535A1 (ja) * | 2019-10-18 | 2021-04-22 | 国立大学法人滋賀医科大学 | 異常幹細胞を標的とする糖尿病治療 |
| CN114828890A (zh) * | 2019-10-18 | 2022-07-29 | 比奥兹普科德公司 | 使用了干细胞迁移剂的糖尿病治疗 |
| US20230173068A1 (en) * | 2020-02-20 | 2023-06-08 | Bio-Thera Solutions, Ltd. | ANTI-TNF-a ANTIBODY FORMULATION, PREPARATION METHOD THEREFOR AND USE THEREOF |
| BR112022021766A2 (pt) * | 2020-04-27 | 2022-12-13 | Janssen Biotech Inc | Materiais e métodos para tratar artrite idiopática juvenil |
| KR20230023663A (ko) | 2020-05-21 | 2023-02-17 | 얀센 바이오테크 인코포레이티드 | Il-23 및 tnf 알파에 대한 항체의 병용 요법으로 염증성 장질환을 치료하는 방법 |
| AU2021287998B2 (en) | 2020-06-11 | 2026-03-12 | Benaroya Research Institute At Virginia Mason | Methods and compositions for preventing type 1 diabetes |
| DE102020129648A1 (de) * | 2020-11-10 | 2022-05-12 | Leopold MTX GmbH | Pharmazeutische zusammensetzung |
| WO2022171685A1 (en) * | 2021-02-10 | 2022-08-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Tnf-alpha blocking agent for preventing, suppressing and/or delaying the onset of type 1 diabetes |
| KR20230152099A (ko) * | 2021-02-26 | 2023-11-02 | 가부시키가이샤 바이오지프코드 | 당뇨병 및 합병증의 신규 치료, 진단 및 검출을 위한 방법 및 제제 |
| US12565529B2 (en) | 2021-05-24 | 2026-03-03 | Provention Bio, Inc. | Methods for treating type 1 diabetes |
| AU2022308201A1 (en) * | 2021-07-09 | 2024-02-22 | Janssen Biotech, Inc. | Manufacturing methods for producing anti-tnf antibody compositions |
| KR20250031013A (ko) * | 2023-08-23 | 2025-03-06 | (주)셀트리온 | TNFα 관련 질환을 치료하는 방법 |
Family Cites Families (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0609722A1 (en) | 1981-09-08 | 1994-08-10 | The Rockefeller University | An in vitro method for detecting the presence of invasive stimuli in mammals |
| US6309640B1 (en) | 1981-09-08 | 2001-10-30 | The Rockefeller University | Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay) |
| US4822776A (en) | 1981-09-08 | 1989-04-18 | The Rockefeller University | Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay) |
| US6419927B1 (en) | 1981-09-08 | 2002-07-16 | Anthony Cerami | Method for reducing adverse effects of a human 70kDa mediator which results from endotoxin stimulation of macrophages |
| US4603106A (en) | 1982-02-22 | 1986-07-29 | The Rockefeller University | Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay) |
| US5700466A (en) | 1981-09-08 | 1997-12-23 | The Rockefeller University | Method of ameliorating or preventing septic shock using a monoclonal antibody specific to cachectin/tumor necrosis factor |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| JPS61100158A (ja) | 1984-10-22 | 1986-05-19 | Fukuarare Honpo:Kk | 納豆付米菓の製造方法およびその製品 |
| DE3650150T2 (de) | 1985-08-16 | 1995-04-27 | The Rockefeller University, New York, N.Y. | Modulator der anabolischen Aktivität und seine Verwendungen. |
| US4870163A (en) | 1985-08-29 | 1989-09-26 | New York Blood Center, Inc. | Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor |
| DE3631229A1 (de) | 1986-09-13 | 1988-03-24 | Basf Ag | Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung |
| EP0279582A3 (en) | 1987-02-17 | 1989-10-18 | Pharming B.V. | Dna sequences to target proteins to the mammary gland for efficient secretion |
| EP0288088B1 (en) | 1987-04-24 | 1994-03-09 | Teijin Limited | Detection of tumor necrosis factor; monoclonal antibody and kit |
| US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
| IL83878A (en) | 1987-09-13 | 1995-07-31 | Yeda Res & Dev | Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it |
| IL98078A0 (en) | 1991-05-07 | 1992-06-21 | Yeda Res & Dev | Pharmaceutical compositions comprising an anticytokyne |
| GB8805792D0 (en) | 1988-03-11 | 1988-04-13 | Celltech Ltd | Medicaments |
| DE3823804A1 (de) | 1988-07-14 | 1990-01-18 | Basf Ag | Neutralisation der in vitro und in vivo toxischen eigenschaften von tnf-(alpha) durch monoklonale antikoerper und den davon abgeleiteten fragmenten |
| NZ229922A (en) | 1988-07-18 | 1992-04-28 | Chiron Corp | Monoclonal antibodies specifically binding cachectin (tumor necrosis factor) and compositions |
| IL94039A (en) | 1989-08-06 | 2006-09-05 | Yeda Res & Dev | Antibodies to tbp - 1 and their use |
| JPH02227095A (ja) | 1988-10-24 | 1990-09-10 | Otsuka Pharmaceut Co Ltd | モノクローナル抗体 |
| US5360716A (en) | 1988-10-24 | 1994-11-01 | Otsuka Pharmaceutical Co., Ltd. | Human tumor necrosis factor αspecific monoclonal antibody and method for detecting human tumor necrosis factor α |
| US5223395A (en) | 1988-12-01 | 1993-06-29 | Centocor, Inc. | Immunometric assays for tumor necrosis factor-alpha and methods for preventing the loss of biological activity of tumor necrosis factor-alpha in biological samples |
| US5342613A (en) | 1988-12-27 | 1994-08-30 | Health Research Inc. | Pharmaceutical compositions and use thereof in the treatment of psoriasis |
| PT92900A (pt) | 1989-01-24 | 1990-07-31 | Sistema de vectores de expressao para a producao de anticorpos monoclonais quimericos | |
| US4936843A (en) | 1989-02-16 | 1990-06-26 | Ace Orthopedic Manufacturing | Kirschner wire clamp and tensioner |
| ATE289350T1 (de) | 1989-04-21 | 2005-03-15 | Amgen Inc | Tnf-rezeptor, tnf bindende proteine und dafür kodierende dnas |
| ES2072330T5 (es) | 1989-05-18 | 2013-06-24 | Yeda Research And Development Co., Ltd. | Proteínas de unión II al Factor de Necrosis Tumoral, su purificación y anticuerpos frente a los mismos |
| US5959087A (en) | 1989-08-07 | 1999-09-28 | Peptide Technology, Ltd. | Tumour necrosis factor binding ligands |
| DE69027121T3 (de) | 1989-08-07 | 2001-08-30 | Peptech Ltd., Dee Why | Bindeligande für tumornekrosisfaktor |
| GB8921123D0 (en) | 1989-09-19 | 1989-11-08 | Millar Ann B | Treatment of ards |
| CA2032191C (en) | 1989-12-13 | 1999-05-18 | David Wallach | Expression of the recombinant tumor necrosis factor binding protein i (tbp-i) |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| DE4037604A1 (de) | 1990-04-25 | 1991-10-31 | Bayer Ag | Verwendung von anti-tnf-antikoerpern als arzneimittel bei der behandlung von ischaemien und deren folgen |
| GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| GB9015908D0 (en) | 1990-07-19 | 1990-09-05 | Celltech Ltd | Multivalent immunoglobulin |
| GB9022648D0 (en) | 1990-10-18 | 1990-11-28 | Charing Cross Sunley Research | Polypeptide and its use |
| US5958413A (en) | 1990-11-01 | 1999-09-28 | Celltech Limited | Use of antibodies to TNF or fragments derived thereof and xanthine derivatives for combination therapy and compositions therefor |
| GB9109645D0 (en) | 1991-05-03 | 1991-06-26 | Celltech Ltd | Recombinant antibodies |
| GB9028123D0 (en) | 1990-12-28 | 1991-02-13 | Erba Carlo Spa | Monoclonal antibodies against human tumor necrosis factor alpha |
| ATE190629T1 (de) | 1991-01-18 | 2000-04-15 | Amgen Inc | Methoden zur behandlung von durch den tumor nekrose faktor ausgelösten krankheiten |
| EP1097945B1 (en) | 1991-03-18 | 2007-07-04 | New York University | Monoclonal and chimeric antibody specific for human tumor necrosis factor |
| US5919452A (en) | 1991-03-18 | 1999-07-06 | New York University | Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies |
| US5656272A (en) | 1991-03-18 | 1997-08-12 | New York University Medical Center | Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies |
| US6277969B1 (en) | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
| US6284471B1 (en) | 1991-03-18 | 2001-09-04 | New York University Medical Center | Anti-TNFa antibodies and assays employing anti-TNFa antibodies |
| US7192584B2 (en) | 1991-03-18 | 2007-03-20 | Centocor, Inc. | Methods of treating psoriasis with anti-TNF antibodies |
| US5698195A (en) | 1991-03-18 | 1997-12-16 | New York University Medical Center | Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies |
| CA2114015C (en) | 1991-07-25 | 2002-12-10 | Roland A. Newman | Recombinant antibodies for human therapy |
| IE922437A1 (en) | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
| EP0525570A3 (en) | 1991-07-31 | 1993-10-06 | Miles Inc. | Anti-idiotypic antibodies that mimic tnf |
| IL99120A0 (en) | 1991-08-07 | 1992-07-15 | Yeda Res & Dev | Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them |
| NO178839C (no) | 1991-11-25 | 1996-06-12 | Ottestad Nils T | Strömningsregulator for opprettholdelse av en stabil strömningsmengde av et fluidum |
| ES2341666T3 (es) | 1991-12-02 | 2010-06-24 | Medimmune Limited | Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos. |
| DK0585705T3 (da) | 1992-08-28 | 1999-07-26 | Bayer Ag | Anvendelse af monoklone anti-TNF-antistoffer til behandling af bakteriel meningitis |
| AU5152293A (en) | 1992-10-08 | 1994-05-09 | Kennedy Institute Of Rheumatology, The | Treatment of autoimmune and inflammatory disorders |
| EP0671936A1 (en) | 1992-10-15 | 1995-09-20 | Dana-Farber Cancer Institute, Inc. | TREATMENT OF INSULIN RESISTANCE IN OBESITY LINKED TYPE II DIABETES USING ANTAGONISTS TO TNF-$g(a) FUNCTION |
| GB9225448D0 (en) | 1992-12-04 | 1993-01-27 | Erba Carlo Spa | Improved synthesis of polymer bioactive conjugates |
| US5888511A (en) | 1993-02-26 | 1999-03-30 | Advanced Biotherapy Concepts, Inc. | Treatment of autoimmune diseases, including AIDS |
| ES2159529T5 (es) | 1993-03-05 | 2011-03-09 | Bayer Corporation | Anticuerpos monoclonales humanos anti-tnf alfa. |
| SE9302490D0 (sv) | 1993-07-26 | 1993-07-26 | Kabi Pharmacia Ab | New use of old drugs |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| GB9403909D0 (en) | 1994-03-01 | 1994-04-20 | Erba Carlo Spa | Ureido derivatives of naphthalenephosphonic acids and process for their preparation |
| US6190691B1 (en) | 1994-04-12 | 2001-02-20 | Adolor Corporation | Methods for treating inflammatory conditions |
| FR2728793A1 (fr) | 1994-12-28 | 1996-07-05 | Oreal | Utilisation d'un antagoniste d'histamine, d'un antagoniste d'interleukine 1 et/ou d'un antagoniste de tnf-alpha dans une composition cosmetique, pharmaceutique ou dermatologique et composition obtenue |
| CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| DK0929578T3 (da) | 1996-02-09 | 2003-08-25 | Abbott Lab Bermuda Ltd | Humane antistoffer, der binder human TNFalfa |
| GB9702088D0 (en) | 1997-01-31 | 1997-03-19 | Pharmacia & Upjohn Spa | Matrix metalloproteinase inhibitors |
| JPH11127855A (ja) | 1997-10-27 | 1999-05-18 | Japan Energy Corp | 組換え型抗ヒトＴＮＦ−αヒトモノクローナル抗体 |
| UA81743C2 (uk) | 2000-08-07 | 2008-02-11 | Центокор, Инк. | МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ |
| TWI334439B (en) | 2001-08-01 | 2010-12-11 | Centocor Inc | Anti-tnf antibodies, compositions, methods and uses |
| AU2003225976A1 (en) | 2002-03-26 | 2003-10-13 | Centocor, Inc. | Anti-tnf antibodies, compositions, methods and uses |
| US20040219142A1 (en) * | 2002-07-19 | 2004-11-04 | Abbott Laboratories S.A. | Treatment of skin and nail disorders using TNFalpha inhibitors |
| TWI439284B (zh) * | 2004-04-09 | 2014-06-01 | 艾伯維生物技術有限責任公司 | 用於治療ＴＮＦα相關失調症之多重可變劑量療法 |
| WO2006122787A1 (en) * | 2005-05-18 | 2006-11-23 | Ablynx Nv | Serum albumin binding proteins |
| WO2007028106A2 (en) | 2005-08-31 | 2007-03-08 | Centocor, Inc. | Host cell lines for production of antibody constant region with enhanced effector function |
| WO2011017294A1 (en) * | 2009-08-07 | 2011-02-10 | Schering Corporation | Human anti-rankl antibodies |
| WO2012050907A2 (en) * | 2010-09-28 | 2012-04-19 | The Regents Of The University Of California | Gaba agonists in the treatment of disorders associated with metabolic syndrome and gaba combinations in treatment or prophylaxis of type i diabetes |
| CA2902727C (en) * | 2013-03-06 | 2020-08-18 | Protalix Ltd. | Use of plant cells expressing a tnfalpha polypeptide inhibitor in therapy |
-
2017
- 2017-02-01 US US15/421,473 patent/US10465003B2/en not_active Expired - Fee Related
- 2017-02-02 KR KR1020187025344A patent/KR20180105711A/ko not_active Withdrawn
- 2017-02-02 MX MX2018009498A patent/MX2018009498A/es unknown
- 2017-02-02 CN CN201780021320.7A patent/CN109072303A/zh active Pending
- 2017-02-02 US US16/070,385 patent/US20190092849A1/en not_active Abandoned
- 2017-02-02 CA CA3012465A patent/CA3012465A1/en not_active Abandoned
- 2017-02-02 JP JP2018540786A patent/JP2019509988A/ja active Pending
- 2017-02-02 MA MA043982A patent/MA43982A/fr unknown
- 2017-02-02 EP EP17748134.8A patent/EP3411504A4/en not_active Withdrawn
- 2017-02-02 BR BR112018015754A patent/BR112018015754A2/pt not_active IP Right Cessation
- 2017-02-02 AU AU2017215317A patent/AU2017215317A1/en not_active Abandoned
- 2017-02-02 WO PCT/US2017/016175 patent/WO2017136524A2/en not_active Ceased
-
2019
- 2019-08-14 US US16/540,388 patent/US11124565B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| KR20180105711A (ko) | 2018-09-28 |
| US20170247444A1 (en) | 2017-08-31 |
| JP2019509988A (ja) | 2019-04-11 |
| BR112018015754A2 (pt) | 2019-01-29 |
| EP3411504A2 (en) | 2018-12-12 |
| AU2017215317A1 (en) | 2018-08-09 |
| US20190092849A1 (en) | 2019-03-28 |
| CN109072303A (zh) | 2018-12-21 |
| EP3411504A4 (en) | 2019-09-11 |
| US11124565B2 (en) | 2021-09-21 |
| US20190375836A1 (en) | 2019-12-12 |
| US10465003B2 (en) | 2019-11-05 |
| MA43982A (fr) | 2018-12-12 |
| WO2017136524A2 (en) | 2017-08-10 |
| CA3012465A1 (en) | 2017-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018009498A (es) | Anticuerpos anti-tnf, composiciones, métodos y uso para el tratamiento o la prevención de la diabetes tipo 1. | |
| NZ755083A (en) | Anti-tnf antibodies, compositions, and methods for the treatment of active psoriatic arthritis | |
| NZ775762A (en) | Anti-tau antibodies and methods of use | |
| MX2019009377A (es) | Anticuerpos anti-tnf, composiciones y metodos para el tratamiento de la espondilitis anquilosante activa. | |
| MX2018000470A (es) | Moleculas de anticuerpo que se unen al grupo de diferenciacion 22 (cd22). | |
| MX2018000147A (es) | Moleculas de anticuerpo que se unen al grupo de diferenciacion 45 (cd45). | |
| MY191649A (en) | Antibodies to tigit | |
| MD4716B1 (ro) | Anticorpi anti-LAG3 şi fragmente de legare a antigenului | |
| ZA201905866B (en) | Anti-c5 antibodies and uses thereof | |
| MX2022006145A (es) | Anticuerpos trem2 y usos de estos. | |
| PH12015501505A1 (en) | Antibodies that bind to tl1a and their uses | |
| MX2021011167A (es) | Anticuerpos humanizados anti grupo de diferenciacion 19 (cd19) humano y metodos de uso. | |
| MX2018000590A (es) | Moleculas de anticuerpo que se unen a agrupacion de diferenciacion 79 (cd79). | |
| EA201790465A1 (ru) | Антитела, композиции и применение | |
| EP4249515A3 (en) | Humanized or chimeric cd3 antibodies | |
| MX395317B (es) | Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos. | |
| WO2017015622A8 (en) | Gdf11 binding proteins and uses thereof | |
| MX2015005719A (es) | Terapias de combinacion que usan moleculas de union anti-psl y pcrv de pseudomonas. | |
| EP3988673A3 (en) | Variants of tnfsf15 and dcr3 associated with crohn's disease | |
| MX2019011252A (es) | Anticuerpos anti-c5a y usos de los mismos. | |
| TN2017000534A1 (en) | Antibodies that bind to sortilin and inhibit the binding of progranulin | |
| NZ741780A (en) | Anti-htra1 antibodies and methods of use thereof | |
| NZ629553A (en) | Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof | |
| MA40182A (fr) | NOUVEL ANTICORPS ANTI-Tie2 HUMAIN | |
| WO2016057683A3 (en) | Novel anti-nodal antibodies and methods of using same |